A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia
暂无分享,去创建一个
J. Szer | I. Lewis | P. Marlton | A. Schwarer | J. Seymour | J. di Iulio | M. Collins | U. Hahn | K. Bradstock | A. Enno | E. Link | G. Cull
[1] J. Reynolds,et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). , 2012, Blood.
[2] J. Reynolds,et al. Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia , 2012, Haematologica.
[3] A. Wei,et al. Risk factors for early death after high-dose cytosine arabinoside (HiDAC)-based chemotherapy for adult AML , 2012, Leukemia.
[4] I. Bruns,et al. A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] J. Bennett,et al. Anthracycline dose intensification in acute myeloid leukemia. , 2009, The New England journal of medicine.
[6] H. Döhner,et al. High-dose daunorubicin in older patients with acute myeloid leukemia. , 2009, The New England journal of medicine.
[7] P. Johansson,et al. Gut protection by palifermin during autologous haematopoietic SCT , 2009, Bone Marrow Transplantation.
[8] 정용식. Use of chemotherapy and radiation therapy protectants , 2009 .
[9] T. Economopoulos,et al. Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study , 2008, Bone Marrow Transplantation.
[10] S. Cantor,et al. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[11] T. Shea,et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Szer,et al. A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. , 2005, Blood.
[13] T. Shea,et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers , 2017 .
[14] N. Harris,et al. The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.
[15] P. Thall,et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. , 2001, Blood.
[16] J. Matthews,et al. Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia , 2001, Leukemia.
[17] W. Hiddemann,et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. , 1999, Blood.
[18] D. Lacey,et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. , 1998, Cancer research.
[19] M. Grever,et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. , 1996, Blood.
[20] O. Garson,et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. , 1996, Blood.
[21] R. Mayer,et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.
[22] A. Bartolucci,et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] P. Ritch,et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia , 1992 .
[24] C. Schiffer,et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. , 1991, Blood.
[25] F. Mandelli,et al. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia , 1991 .
[26] Janice Gabrilove,et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia , 1991 .
[27] J. Rubin,et al. Purification and characterization of a newly identified growth factor specific for epithelial cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[28] N. Nissen,et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. , 1982, Blood.
[29] J. Goldberg,et al. Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants , 2013, Bone Marrow Transplantation.
[30] M. Patnaik,et al. Anthracycline dose intensification in acute myeloid leukemia. , 2009, The New England journal of medicine.
[31] Anthracycline Dose Intensification in Acute Myeloid Leukemia (AML) , 2009 .
[32] W. Gradishar,et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] P. Ritch,et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. , 1992, Blood.
[34] J. Matthews,et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. , 1990, Blood.
[35] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.